CI-996 

CI-996 is a potent, selective, orally active angiotensin II (Ang II) type 1 (AT1) receptor antagonist. In rat liver membranes CI-996 displaces specifically bind [¹²⁵I]Ang II with an IC₅₀ of 0.8 nM. CI-996 has blood pressure-lowering activity^[1].

In isolated rabbit aorta CI-996 produces a concentration-dependent inhibition of Ang II-induced contraction and decreased the maximal contractile response to Ang II. CI-996 has no effect on the contractile responses to KCl, norepinephrine or endothelin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In anesthetized, ganglionic-blocked rats CI-996 produces dose-dependent inhibition of the Ang II pressor dose-response curve with an IC₅₀ of 6.2 μg/kg/min i.v^[1].
Orally administered CI-996 dose dependently loweres mean arterial blood pressure in conscious renal hypertensive rats, conscious sodium-depleted dogs, conscious sodium-depleted monkeys and conscious renal hypertensive monkeys^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

549.50

C₂₇H₂₂F₃N₇O₃

150438-02-1

O=C(C1=C(N2C(C(C(F)(F)F)=O)=CC=C2)N=C(CCC)N1CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Keiser JA, et al. Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist. J Pharmacol Exp Ther. 1995 Mar;272(3):963-9.